Correlation Between Serum and CSF Concentrations of Midazolam and 1-Hydroxy-Midazolam in Critically Ill Neurosurgical Patients

被引:0
|
作者
Farrar, Julie E. [1 ]
Stefanos, Sylvia S. [2 ]
Cava, Luis [3 ]
Kiser, Tyree H. [4 ]
Mueller, Scott W. [5 ]
Neumann, Robert [3 ]
Reynolds, Paul M. [6 ]
Sherman, Deb S. [5 ]
Maclaren, Robert [4 ]
机构
[1] Univ Tennessee, Coll Pharm, 881 Madison Ave, Memphis, TN 38163 USA
[2] Houston Methodist Hosp, Houston, TX USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[5] Univ Colorado Hosp, Aurora, CO USA
[6] Rocky Mt Reg VA Med Ctr, Denver, CO USA
关键词
midazolam; cerebrospinal fluid; critical care; neurosurgery; PHARMACOKINETICS; SEDATION;
D O I
10.1177/10600280241271130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Midazolam (MZ) is commonly used in critically ill neurosurgical patients. Neuro-penetration of MZ and its metabolite, 1-hydroxy-midazolam (1-OH-MZ), is not well characterized. Objective: This study evaluated correlations between serum and cerebrospinal fluid (CSF) concentrations of MZ and 1-OH-MZ and assessed implications on patient sedation. Methods: Adults in the neurosurgical intensive care unit (ICU) with external ventricular drains receiving MZ via continuous infusion were prospectively studied. Serum and CSF samples were obtained 12-24 h and 72-96 h after initiation, and concentrations were determined in duplicate by high-performance liquid chromatography with tandem mass spectrometry. Bivariate correlation analyses used Pearson coefficient. Results: A total of 31 serum and CSF samples were obtained from 18 subjects. At sampling, mean MZ infusion rate was 3.9 +/- 4.4 mg/h, and previous 12-h cumulative dose was 51.4 +/- 78.2 mg. Mean concentrations of MZ and 1-OH-MZ in serum and CSF were similar between timepoints. Similarly, ratios of 1-OH-MZ to MZ in serum and CSF remained stable over time. Serum MZ (126.2 +/- 89.3 ng/mL) showed moderate correlation (r(2) = 0.68, P < 0.001) with serum 1-OH-MZ (17.7 +/- 17.6 ng/mL) but not CSF MZ (3.9 +/- 2.5 ng/mL; r(2) = 0.24, P = 0.005) or CSF 1-OH-MZ (2.5 +/- 0.6 ng/mL; r(2) = 0.47, P = 0.30). CSF MZ did not correlate with CSF 1-OH-MZ (r(2) = 0.003, P < 0.001). Mean serum ratio of 1-OH-MZ to MZ (0.14 +/- 0.2 ng/mL) did not correlate with CSF ratio (1.06 +/- 0.83 ng/mL; r(2) = 0.06, P = 0.19). Concentrations and ratios were unrelated to MZ infusion rate or 12-h cumulative dose. Sedation was weakly correlated with CSF 1-OH-MZ, but not with serum MZ, serum 1-OH-MZ, or CSF MZ. Conclusion and Relevance: Continuous infusions of MZ result in measurable concentrations of MZ and 1-OH-MZ in CSF; however, CSF concentrations of MZ and 1-OH-MZ poorly represent serum concentrations or dosages. Accumulation of MZ and 1-OH-MZ in serum or CSF over time was not evident. Concentrations of MZ and 1-OH-MZ do not predict sedation levels, reinforcing that pharmacodynamic assessments are warranted.
引用
收藏
页码:244 / 249
页数:6
相关论文
共 50 条
  • [1] Investigating the Relationship Between Midazolam Serum Concentrations and Paediatric Delirium in Critically Ill Children
    Marongiu, Sabrina
    Bolhuis, Mathieu S.
    Touw, Daan J.
    Kneyber, Martin C. J.
    PEDIATRIC REPORTS, 2025, 17 (01):
  • [2] Pharmacokinetics of midazolam in critically ill pediatric patients
    Nahara, MC
    McMorrow, J
    Jones, PR
    Anglin, D
    Rosenberg, R
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2000, 25 (3-4) : 219 - 221
  • [3] Pharmacokinetics of midazolam in critically ill pediatric patients
    Milap C. Nahara
    Julie McMorrow
    Paul R. Jones
    David Anglin
    Robert Rosenberg
    European Journal of Drug Metabolism and Pharmacokinetics, 2000, 25 : 219 - 221
  • [4] Clinical pharmacokinetic monitoring of midazolam in critically ill patients
    Spina, Sean P.
    Ensom, Mary H. H.
    PHARMACOTHERAPY, 2007, 27 (03): : 389 - 398
  • [5] MIDAZOLAM INFUSIONS IN CRITICALLY ILL PATIENTS
    SHELLY, MP
    SULTAN, MA
    BODENHAM, A
    PARK, GR
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 1991, 8 (01) : 21 - 27
  • [6] Effect of midazolam on delirium in critically ill patients: a propensity score analysis
    Shi, He-Jie
    Yuan, Rui-Xia
    Zhang, Jun-Zhi
    Chen, Jia-Hui
    Hu, An-Min
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (04) : 1 - 10
  • [7] Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients
    MacLaren, R
    Sullivan, PW
    PHARMACOTHERAPY, 2005, 25 (10): : 1319 - 1328
  • [8] Outcomes in Critically Ill Patients Sedated with Intravenous Lormetazepam or Midazolam: A Retrospective Cohort Study
    Weiss, Bjoern
    Hilfrich, David
    Vorderwuelbecke, Gerald
    Heinrich, Maria
    Grunow, Julius J.
    Paul, Nicolas
    Kruppa, Jochen
    Neuner, Bruno
    Drexler, Berthold
    Balzer, Felix
    Spies, Claudia D.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (18)
  • [9] THE EFFECTS OF MIDAZOLAM ON THE EEG DURING SEDATION OF CRITICALLY ILL PATIENTS
    VESELIS, RA
    REINSEL, R
    MARINO, P
    SOMMER, S
    CARLON, GC
    ANAESTHESIA, 1993, 48 (06) : 463 - 470
  • [10] Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients
    Beigmohammadi, Mohammad Taghi
    Hanifeh, Majid
    Rouini, Mohammad Reza
    Sheikholeslami, Behjat
    Mojtahedzadeh, Mojtaba
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2013, 12 (02): : 483 - 488